Literature DB >> 22617153

The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis.

Seung Up Kim1, Hyun Jung Oh, Ian R Wanless, Sarah Lee, Kwang-Hyub Han, Young Nyun Park.   

Abstract

BACKGROUNDS & AIMS: The clinical severity of cirrhosis varies widely. We investigated whether histological sub-classification of cirrhosis using the Laennec system can discriminate different outcomes among patients with cirrhosis.
METHODS: One hundred and seventy-five patients with chronic liver disease who underwent liver biopsy and showed stage 3 or 4 fibrosis between January 2001 and December 2008 were prospectively enrolled. Cirrhosis was sub-classified into three groups (4A, 4B, and 4C) according to the Laennec system. The end point was liver-related event (LRE) occurrence, including decompensation, hepatocellular carcinoma, and liver-related death.
RESULTS: The median age of the patients (110 men, 65 women) was 55 years. Stages 3, 4A, 4B, and 4C were identified in 46 (26.3%), 16 (9.1%), 82 (46.9%), and 31 (17.7%) patients, respectively. During the follow-up period, LREs occurred in 32 (18.3%) patients: 4 (8.7%) with stage 3, 2 (12.5%) with stage 4A, 17 (20.7%) with stage 4B, and 9 (29.0%) with stage 4C. In a multivariate analysis, histological sub-classification of cirrhosis independently predicted LRE occurrence. While patients with stage 4A tended to be at higher risk of LRE occurrence than those with stage 3, patients with stages 4B and 4C had significantly higher risks of LRE occurrence, with hazard ratios of 6.158 (p=0.016) and 8.945 (p=0.004), respectively.
CONCLUSIONS: Histological sub-classification of cirrhosis using the Laennec system can be used to assess the risk of LRE occurrence among patients with cirrhosis. Our study provides a solid basis for further studies of non-invasive methods for monitoring the risk of LRE occurrence and will help physicians to establish optimum treatment strategies.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617153     DOI: 10.1016/j.jhep.2012.04.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

Review 1.  Four-dimensional flow magnetic resonance imaging in cirrhosis.

Authors:  Zoran Stankovic
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Invasive and non-invasive diagnosis of cirrhosis and portal hypertension.

Authors:  Moon Young Kim; Woo Kyoung Jeong; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Evolution of the liver biopsy and its future.

Authors:  Dhanpat Jain; Richard Torres; Romulo Celli; Jeremy Koelmel; Georgia Charkoftaki; Vasilis Vasiliou
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

4.  Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease.

Authors:  Yuri Cho; Youn I Choi; Sohee Oh; Jimin Han; Sae Kyung Joo; Dong Hyeon Lee; Yong Jin Jung; Byeong Gwan Kim; Kook Lae Lee; Won Kim
Journal:  Hepatol Int       Date:  2019-12-19       Impact factor: 6.047

Review 5.  Molecular prognostic prediction in liver cirrhosis.

Authors:  Nicolas Goossens; Shigeki Nakagawa; Yujin Hoshida
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

6.  Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.

Authors:  Mi Young Jeon; Hye Won Lee; Seung Up Kim; Ja Yoon Heo; Sojung Han; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2017-02-21       Impact factor: 6.047

7.  The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients.

Authors:  Akhmad Makhmudi; Reinaldo Supanji; Bayu Pratama Putra
Journal:  Pediatr Surg Int       Date:  2019-09-23       Impact factor: 1.827

Review 8.  Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.

Authors:  Yan Wang; Jin-Lin Hou
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

Review 9.  Bone marrow derived stem cells for the treatment of end-stage liver disease.

Authors:  Cristina Margini; Ranka Vukotic; Lucia Brodosi; Mauro Bernardi; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 10.  Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.

Authors:  Prodromos Hytiroglou; Neil D Theise
Journal:  Virchows Arch       Date:  2018-03-27       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.